Isolated limb perfusion for unresectable melanoma of the extremities

Archives of Surgery

Volumn 139, Issue 11, 2004, Pages 1237-1242

  Noorda, Eva M ^a,c   Vrouenraets, Bart C ^a   Nieweg, Omgo E ^a   Van Geel, Bert N ^b   Eggermont, Alexander M M ^b   Kroon, Bin B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIMB PERFUSION; LIMB SALVAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NETHERLANDS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; LIMB SALVAGE; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 7744229202     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.139.11.1237     Document Type: Article

References (30)

1. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg. 1996;83:509-512.
2. Strobbe LJ, Nieweg OE, Kroon BBR. Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol. 1997;23:435-438.
3. Overgaard J, Gonzalez GD, Hulshof MC, et al; European Society for Hyperthermic Oncology. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet. 1995;345:540-543.
4. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
5. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998;16:2921-2929.
6. Creech DG, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilising an extracorporeal circuit. Ann Surg. 1958;148:616-632.
7. Fraker O, Alexander H, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma [abstract]. Ann Surg Oncol. 2002;9:S8.
8. Rossi CR, Foletto M, Pilati P, Mocellin S, Use M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol. 2002;29:400-409.
9. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14:479-489.
10. Di Filippo F, Calabro A, Giannarelli D, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989;63:2551-2561.
11. Vrouenraets BC, Hart GA, Eggermont AMM, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522-530.
12. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988;14:101-110.
13. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-910.
14. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979.
15. Vrouenraets BC, Nieweg OE, Kroprt BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319-1328.
16. Klaase JM, Kroon BBR, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994;115:39-45.
17. Vaglini M, Santinami M, Manzi R, et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma): dose-finding experience at the National Cancer Institute of Milan. Melanoma Res. 1994;4(suppl 1):35-38.
18. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III: results of a multicentre pilot study. Melanoma Res. 1994;4(suppl 1):21-26.
19. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999;9:491-502.
20. Eggermont AMM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv. 1996;26:335-349.
21. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
22. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur J Cancer. 1995;31A:1009-1016.
23. Klaase JM, Kroon BBR, Eggermont AMM, et al. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer. 1995;31A:58-63.
24. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BBR. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14:224-231.
25. Vrouenraets BC, Eggermont AMM, Hart AAM, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390-395.
26. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
27. Zogakis TG, Bartlett DL, Libutti SK, et al. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol. 2001;8:771-778.
28. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994;178:564-572.
29. Fenn NJ, Horgan K, Johnson RC, Hughes LE, Mansel RE. A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol. 1997;23:6-9.
30. Hafstrom L, Rudenstam CM, Blomquist E, et al: Swedish Melanoma Study Group. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. J Clin Oncol. 1991;9:2091-2094.